Hls Therapeutics Stock Cash And Equivalents
| HLS Stock | CAD 3.65 0.15 4.29% |
HLS Therapeutics fundamentals help investors to digest information that contributes to HLS Therapeutics' financial success or failures. It also enables traders to predict the movement of HLS Stock. The fundamental analysis module provides a way to measure HLS Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HLS Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Cash And Equivalents | 18.7 M | 20.9 M |
HLS | Cash And Equivalents |
HLS Therapeutics Company Cash And Equivalents Analysis
HLS Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current HLS Therapeutics Cash And Equivalents | 20.72 M |
Most of HLS Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLS Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HLS Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for HLS Therapeutics is extremely important. It helps to project a fair market value of HLS Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since HLS Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HLS Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HLS Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, HLS Therapeutics has 20.72 M in Cash And Equivalents. This is 97.48% lower than that of the Pharmaceuticals sector and 94.24% lower than that of the Health Care industry. The cash and equivalents for all Canada stocks is 99.23% higher than that of the company.
HLS Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLS Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HLS Therapeutics could also be used in its relative valuation, which is a method of valuing HLS Therapeutics by comparing valuation metrics of similar companies.HLS Therapeutics is currently under evaluation in cash and equivalents category among its peers.
HLS Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of HLS Therapeutics from analyzing HLS Therapeutics' financial statements. These drivers represent accounts that assess HLS Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of HLS Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 557.2M | 439.1M | 371.4M | 235.1M | 123.9M | 70.9M | |
| Enterprise Value | 603.3M | 525.6M | 447.8M | 311.8M | 189.6M | 199.0M |
HLS Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 183.68 M | ||||
| Shares Outstanding | 31.79 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 65.10 % | ||||
| Number Of Shares Shorted | 4.64 K | ||||
| Price To Book | 0.99 X | ||||
| Price To Sales | 1.95 X | ||||
| Revenue | 63.07 M | ||||
| Gross Profit | 50.76 M | ||||
| EBITDA | 21.94 M | ||||
| Net Income | (27.53 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 87.62 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | 15.79 M | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.98) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 111.28 M | ||||
| Total Asset | 209.06 M | ||||
| Retained Earnings | (175.46 M) | ||||
| Working Capital | 17.41 M | ||||
| Net Asset | 209.06 M | ||||
| Last Dividend Paid | 0.076 |
About HLS Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLS Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLS Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLS Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.